Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

3 Coronavirus Stocks to Stay Miles Away From in 2021

By Alex Carchidi - Jan 12, 2021 at 7:05AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Their coronavirus projects fell behind, faltered, or failed.

The new year has already been packed with challenges -- new and old. Top of mind is that thousands of people are dying of coronavirus-related causes every day. We're lucky to have a few drugs that can prevent or treat COVID-19, and we'll need even more as we move forward. Vaccines from Moderna and the team of Pfizer and BioNTech, in particular, have brought a possible end to the pandemic into sight. Investors who bought stock in these businesses, and others making safe and efficacious medicines, are doubly lucky. But picking the right coronavirus stocks in 2021 is going to be a different ballgame, and a risky one at that.

There's still plenty of room for new competitors in the market for coronavirus drugs. But showing up to the market late or with a weak product might not to be enough to succeed. The companies I'll discuss today might grow alongside the wider market in 2021 -- after all, they're massive enterprises, and their coronavirus programs only constitute a small part of their potential revenue. Nonetheless, because of their recent stumbles, I don't think that they will outperform their competitors who have successful vaccines or therapies, so you should probably steer clear.

A woman gestures with her hand that the viewer should keep their distance.

Image source: Getty Images.

1. Sanofi

One of Sanofi's ( SNY -1.51% ) coronavirus vaccine programs was thrown off the rails in early December when it reported less-than-satisfactory results from phase 2 clinical trials. In short, a manufacturing issue caused doses of the vaccine to not have enough of its active ingredient, the spike protein of the coronavirus. Subsequently, participants over age 60 were not protected as effectively. The company doesn't need to go all the way back to the drawing board, but it will need to reformulate the vaccine and show regulators that it has solved the issue.

Sanofi's vaccine may not get regulatory approval until the second half of the year, if it does at all. This means that rivals like Pfizer will have a solid head start when it comes to reporting vaccine revenue, making them preferable investments. It also means that Sanofi won't benefit nearly as much from hype-building clinical data updates during the development process. Of course, Sanofi has a plethora of non-coronavirus projects in the works, so its revenue will still likely grow this year. But, unless you were already interested in investing in the company for the expected revenue from these other programs, it's probably better to wait until its vaccine is back on track before investing.

2. Merck

The pharma giant Merck ( MRK -1.07% ) has been especially slow to stir throughout the pandemic. Its vaccine program only entered its first phase of clinical trials in September, when competitors were in the midst of phase 3 clinical trials. Merck's therapeutics projects are a bit further ahead of its vaccine effort. It acquired a small biotech company called OncoImmune in November for $425 million to get access to its drug MK-7110, which may be effective at reducing inflammation during severe coronavirus infections. MK-7110 is in phase 3 trials right now. Merck also has an antiviral called MK-4482 in phase 2 trials.

Preliminary findings show that MK-7110 could be effective at reducing the risk of death from COVID-19. That's extremely promising, but there's one problem: It will be competing with the cheap generics that are already being used for that purpose, including steroids like dexamethasone. If MK-7110 can't be used alongside these drugs in the same patient, or if it doesn't provide better results in a head-to-head comparison, there's little reason to believe that it will get much traction.

^SPX Chart

^SPX data by YCharts

3. CSL Limited

CSL Limited's ( CSL -0.07% ) coronavirus vaccine program crashed and burned early in December. The problem with CSL's candidate was that it caused some of its clinical trial participants to falsely test positive for HIV. This finding wasn't entirely a surprise, as the vaccine used some components adapted from HIV. Nobody was at risk of actually getting HIV from the inoculation, but the fact that the vaccine interfered with accurate HIV testing made it unsuitable for widespread distribution and use in public health. So, CSL terminated clinical development, and major customers, like the government of Australia, canceled their preorders.

The company won't be benefiting whatsoever from its sunk costs. While it does have a couple of coronavirus therapeutics in clinical development, it's unclear how close these programs are to getting regulatory approval. In other words, CSL might not have any new revenue from its coronavirus efforts in 2021, and that makes it a tough sell to investors.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
$74.09 (-1.07%) $0.80
Sanofi Stock Quote
$47.48 (-1.51%) $0.73
Pfizer Inc. Stock Quote
Pfizer Inc.
$53.27 (1.66%) $0.87
Moderna, Inc. Stock Quote
Moderna, Inc.
$343.26 (-6.85%) $-25.25
BioNTech SE Stock Quote
BioNTech SE
$338.96 (-6.50%) $-23.56
CSL Limited Stock Quote
CSL Limited
$306.79 (-0.07%) $0.21

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/30/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.